Assessing adverse event (AE) frequency of eight potentially interacting medications (PIM) with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) utilizing Phase III clinical trial data
ANTIVIRAL THERAPY（2016）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要